Accessibility Menu
 
Larimar Therapeutics logo

Larimar Therapeutics

(NASDAQ) LRMR

Current Price$4.78
Market Cap$498.80M
Since IPO (2020)-61%
5 Year-67%
1 Year+118%
1 Month-13%

Larimar Therapeutics Financials at a Glance

Market Cap

$498.80M

Revenue (TTM)

$0.00

Net Income (TTM)

$165.67M

EPS (TTM)

$-2.21

P/E Ratio

-2.17

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$4.78

Volume

38,361

Open

$4.55

Previous Close

$4.78

Daily Range

$4.55 - $4.78

52-Week Range

$1.61 - $6.42

LRMR News

LRMR: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Larimar Therapeutics

Industry

Biotechnology

Employees

71

CEO

Carole S. Ben-Maimon, MD

Headquarters

Bala Cynwyd, PA 19004, US

LRMR Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-133%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-46.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$498.80M

Shares Outstanding

104.13M

Volume

38.36K

Short Interest

0.00%

Avg. Volume

4.19M

Financials (TTM)

Gross Profit

$350.00K

Operating Income

$172.50M

EBITDA

$172.50M

Operating Cash Flow

$113.20M

Capital Expenditure

$91.00K

Free Cash Flow

$113.29M

Cash & ST Invst.

$136.85M

Total Debt

$4.07M

Larimar Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$87.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$498.80M

N/A

Market Cap/Employee

$7.67M

N/A

Employees

65

N/A

Net Income

$62.50M

-116.8%

EBITDA

$63.93M

-104.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$132.78M

-25.5%

Accounts Receivable

$747.00K

-29.1%

Inventory

$0.00

N/A

Long Term Debt

$2.96M

-27.0%

Short Term Debt

$1.10M

+4.2%

Return on Assets

-1.14%

N/A

Return on Invested Capital

-2.13%

N/A

Free Cash Flow

$38.53M

-75.2%

Operating Cash Flow

$38.53M

-76.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DBVTDBV Technologies S.A.
$21.06+2.73%
LXEOLexeo Therapeutics, Inc. Common Stock
$5.72+0.88%
KYTXKyverna Therapeutics, Inc.
$8.87+1.14%
ENGNenGene Holdings Inc.
$6.69-1.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
NVDANvidia
$177.39+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
INTCIntel
$50.38+0.05%

Questions About LRMR

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.